TD Asset Management
MRSN

TD Asset Management’s Mersana Therapeutics MRSN Stock Holding History

TD Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,802
Closed -$425K – 1526
2021
Q3 		$425K Sell
1,802
-1,156
-39% -$338K ﹤0.01% 1416
2021
Q2 		$813K Sell
2,958
-536
-15% -$203K ﹤0.01% 1297
2021
Q1 		$1.41M Sell
3,494
-98
-3% -$47.5K ﹤0.01% 1191
2020
Q4 		$2.39M Buy
3,592
+1,320
+58% +$734K ﹤0.01% 987
2020
Q3 		$1.06M Buy
2,272
+1,336
+143% +$675K ﹤0.01% 1076
2020
Q2 		$547K Buy
+936
New +$320K ﹤0.01% 1191

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TD Asset Management's MRSN Position: Q4 2021 in Review

TD Asset Management sold out of Mersana Therapeutics (MRSN) in Q4 2021, closing a stake of 1,802 shares — an estimated $425K sold.

TD Asset Management first reported a position in MRSN in Q2 2020 and held it in 6 quarters. The position peaked at $2.39M in Q4 2020. 122 funds tracked by Wall St. Rank hold MRSN as of Q4 2021.

  • TD Asset Management reported no remaining Mersana Therapeutics position as of Q4 2021 after selling out during the quarter.
  • TD Asset Management sold 1,802 Mersana Therapeutics shares in Q4 2021, an estimated $425K.
  • TD Asset Management first reported a position in Mersana Therapeutics in Q2 2020 and held it in 6 quarters.
  • TD Asset Management's Mersana Therapeutics position peaked at $2.39M in Q4 2020.
  • 122 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2021.

Based on TD Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.